

—

reauthorization

If all the above requirements are met, the medication will be approved for an additional 12 months.

Cancer diagnosis

CareSource considers mitoxantrone not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

DATE	ACTION/DESCRIPTION
06/12/2017	
12/06/2017	
07/06/2022	

Lancet Neurol